NYSE: MRKMerck & Co Inc Stock
$101.03-0.80 (-0.79%)
Updated Dec 2, 2025
MRK Price
$101.03
Fair Value Price
N/A
Market Cap
$250.76B
52 Week Low
$73.31
52 Week High
$105.84
P/E
13.35x
P/B
4.84x
P/S
3.26x
PEG
1.19x
Dividend Yield
3.21%
Revenue
$64.24B
Earnings
$19.03B
Gross Margin
77.2%
Operating Margin
35.93%
Profit Margin
29.6%
Debt to Equity
1.5
Operating Cash Flow
$17B
Beta
0.29
Next Earnings
Feb 3, 2026
Ex-Dividend
Dec 15, 2025
Next Dividend
Jan 8, 2026
MRK Overview
Merck & Company Incorporated develops and distributes prescription medicines, vaccines, biologic therapies, and animal health products. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MRK's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
MRK
Ranked#6 of 19
Ranked#6 of 19
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.51 | A | |
| $48.25 | A | |
| $48.27 | A |
Be the first to know about important MRK news, forecast changes, insider trades & much more!
MRK News
Overview
Due Diligence Score
–
Industry Average (39)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MRK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRK ($101.03) is trading above its intrinsic value of $75.43, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRK is good value based on its earnings relative to its share price (13.35x), compared to the US market average (45.71x)
P/E vs Market Valuation
MRK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MRK due diligence checks available for Premium users.
Valuation
MRK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
13.35x
Industry
45.16x
Market
45.71x
MRK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MRK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MRK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.84x
Industry
6.8x
MRK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRK price to earnings growth (PEG)
For valuing profitable companies with growth potential
MRK is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
MRK's financial health
Profit margin
Revenue
$17.3B
Net Income
$5.8B
Profit Margin
33.5%
MRK's Earnings (EBIT) of $23.08B... subscribe to Premium to read more.
Interest Coverage Financials
MRK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$129.5B
Liabilities
$77.6B
Debt to equity
1.5
MRK's short-term assets ($47.56B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRK's long-term liabilities ($49.01B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MRK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.8B
Investing
-$283.0M
Financing
$2.6B
MRK's operating cash flow ($17.07B)... subscribe to Premium to read more.
Debt Coverage Financials
MRK vs General Drug Manufacturer Stocks
Merck & Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.